BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.
Bristol Myers Squibb (NYSE:BMY) is rolling out an AI driven overhaul of its procurement operations, using tools designed to shorten sourcing timelines and reshape internal buying processes. The compan
Bristol Myers Squibb (BMY) closed at $56.87 in the latest trading session, marking a +2.28% move from the prior day.
Takeda said Thursday its AI-designed psoriasis pill, zasocitinib, easily beat Bristol's Sotyktu in a head-to-head study.
"Productivity initiatives" could prove key in maintaining this pharma company's decades-long dividend growth streak.
The results support Takeda’s long-held belief in zasocitinib’s superiority and could help it gain a commercial advantage over Bristol’s therapy.
Bristol Myers Squibb Foundation, linked to NYSE:BMY, is rolling out a new lung cancer detection and care model in underserved Brazilian communities. The program uses mobile CT units, telemedicine, and
Earned income has a ceiling. Hours in a day, headcount budgets, layoff cycles, and corporate restructurings all cap how much a paycheck can deliver. Passive income flips that dynamic. A properly built
View interactive chart, options flow, and AI analysis for BMY on Zorveq Finance.
Open BMY Chart & Analysis →